Finding – Page 16

Unlocking Health Equity: Leveraging Comprehensive SDOH Market Insights for Enhanced Treatment, Access, and Adherence

10 months ago talkbio0Tagged Adherence, Adherence (attribute), Data Analytics, Health care facility, Health Equity, Market, outcomes, public health medicine (field), Social Determinants of Health

Social Determinants of Health (SDOH), Health Equity, Market Insights, Treatment Access, Adherence, Healthcare Outcomes, Data Analytics, Public Health

GUBamy, a Weekly Amylin Agonist, Shows Promising Weight Loss and Tolerability in Phase 1 Trial

10 months ago talkbio0Tagged Agonist, Amylin, GUBamy, long-acting, Obesity, phase 1 trial, Weight Loss

Amylin agonist, Obesity treatment, Weight loss, Phase 1 trial, GUBamy, Long-acting amylin agonist

UK Health Secretary Warns Against Misuse of GLP-1 Weight Loss Drugs for Aesthetic Purposes

10 months ago talkbio0Tagged agonists, Cautionary Warning, Esthetics (discipline), Glucagon-Like Peptide 1, health secretary, MHRA, MISUSE, UK, Weight Loss, Weight-Loss Agents

GLP-1 agonists, weight loss drugs, misuse, aesthetic weight loss, UK health secretary, MHRA warnings

Rapport Therapeutics Faces Regulatory Hurdles in Pain Treatment Trials

10 months ago talkbio0Tagged Clinical Development, RAP-219, Rapport Therapeutics, regulatory, treatment pain

Rapport Therapeutics, pain treatment trials, regulatory challenges, RAP-219, clinical development

Advancements in Bispecific Antibody Therapies: Recent Deals and Clinical Data on VEGF-Targeting Agents

10 months ago talkbio0Tagged Age related macular degeneration, Agreement, Antibodies, Bispecific, Cancer Therapeutic Procedure, Clinical Trials, Exudative age-related macular degeneration, Neovascular, Royalty, Vascular Endothelial Growth Factor A

Bispecific antibodies, VEGF, neovascular age-related macular degeneration (nAMD), cancer therapy, clinical trials, royalty agreements.

AstraZeneca Advances in Obesity Market with ECC5004 Deal and Promising Clinical Data

10 months ago talkbio0Tagged AstraZeneca, cardiometabolic diseases, GLP-1RA, Obesity, Weight Loss

AstraZeneca, obesity, ECC5004, GLP-1RA, cardiometabolic diseases, weight loss market

FDA Raises Sterility and Quality Concerns at Mark Cuban’s Dallas Drug Compounding Facility

10 months ago talkbio0Tagged concerns, Cost Plus, Cuban, Dallas, Dallas facility, Infertility, Massive, Quality, United States Food and Drug Administration

Mark Cuban, Cost Plus Drugs, FDA, sterility concerns, quality issues, drug compounding, Dallas facility

GSK’s Vaccine Sales Plummet in Q3, Highlighting Reduced Demand and Market Challenges

11 months ago talkbio0Tagged Arexvy, Demand (clinical), Reduced, Shingrix, SmithKline Beecham, third quarter, Vaccines

GSK, vaccine sales, third quarter, reduced demand, Arexvy, Shingrix, influenza vaccine

Alto Neuroscience’s Mid-Stage Depression Trial Fails, Casting Doubts on Neuropsychiatry R&D Strategy

11 months ago talkbio0Tagged Alto, ALTO-100, Biological Markers, Clinical Failure, depression trial, Neuroscience discipline, R&D

Alto Neuroscience, depression trial, neuropsychiatry R&D, ALTO-100, biomarker strategy, clinical failure

Vertex’s Non-Opioid Pain Drug Suzetrigine Nears FDA Approval: A Breakthrough in Acute Pain Management

11 months ago talkbio0Tagged acute pain management, addiction, Approved, Feeling relief, non-opioid pain drug, Opioid Epidemic, Pain, Risk, signal inhibitor, Suzetrigine, United States Food and Drug Administration

Suzetrigine, Non-opioid pain drug, Acute pain management, FDA approval, Vertex Pharmaceuticals, NaV1.8 pain signal inhibitor, Opioid epidemic, Pain relief without addiction risk